BUSINESS
Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
Hisamitsu Pharmaceutical has initiated a PIII clinical study of its transdermal Parkinson’s disease treatment HP-3000 (development code; ropinirole HCl) in Japan, it said on April 14. The study is a blind study to evaluate the efficacy and safety of once…
To read the full story
Related Article
- Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
October 1, 2018
- Hisamitsu’s Transdermal Parkinson’s Drug Hits Primary Endpoint
February 28, 2018
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





